(PDF) Upfront Treatment With the First and

Upfront Treatment With the First and Second-Generation Tyrosine Kinase Inhibitors in Ph-Positive Acute Lymphoblastic Leukemia

Oncotarget - United States

doi 10.18632/oncotarget.22206

Full Text

Abstract

Available in full text

Categories

Date

October 31, 2017

Authors

Publisher

Impact Journals, LLC

Related search

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

English

Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Current Hematologic Malignancy Reports

Cancer Research

English

Arterial Events in Patients With Chronic Myeloid Leukemia Receiving Treatment With Second Generation Tyrosine Kinase Inhibitors

Klinicheskaya Onkogematologiya/Clinical Oncohematology

English

Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

English

Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor

English

Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

English

The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

English

Philadelphia Chromosome-Positive Acute Myelocytic Leukemia With French-American-British M2 Morphology, Refractory to Tyrosine Kinase Inhibitors

Tenri Medical Bulletin

English